Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 tablet vs capsule formulation in healthy subjects
NCT03340753Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ocederenone (3 arms), sponsored by KBP Biosciences. Primary endpoint: Area Under the Curve to Last Measurable Concentration at 312 hours. Started Oct 2017; status: completed.
02
Drugs
ocederenone
Beyond the preview
Go deeper on NCT03340753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340753.